Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448669 · ClinicalTrials.gov registry record · Phase 2
Botswana TDF/FTC Oral HIV Prophylaxis Trial
A Phase 2 study of HIV Infections, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,219
- Enrollment target
- 2
- Study locations
NCT00448669 is a Phase 2 study of HIV Infections that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 1,219 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (175% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT00448669, a Phase 2 study of HIV Infections, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,219 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study tested whether taking a pill of tenofovir and emtricitabine (two antiretroviral medicines) was safe for sexually-active young adults in Botswana without HIV infection and whether it reduced their risk of getting an HIV infection.
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
Study Locations (2)
Georgia
- Centers for Disease Control and Prevention - Atlanta
Other
- BOTUSA HIV Prevention Research Unit - Gaborone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,219 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00448669
The ClinicalTrials.gov registry entry for NCT00448669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,219 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (175% higher). The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT00448669 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Other.
Frequently Asked Questions
What is clinical trial NCT00448669 about?
NCT00448669 is a clinical study titled "Botswana TDF/FTC Oral HIV Prophylaxis Trial". This study tested whether taking a pill of tenofovir and emtricitabine (two antiretroviral medicines) was safe for sexually-active young adults in Botswana without HIV infection and whether it reduced their risk of getting an HIV infection.
What is the current status of trial NCT00448669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,219 participants. The study started on 2007-03. Estimated completion is 2011-03.
What conditions does trial NCT00448669 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00448669?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (DRUG).
Who is sponsoring clinical trial NCT00448669?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00448669 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.